Empagliflozin and Ethacrynic Sodium Injection

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Empagliflozin may add to the diuretic effects of ethacrynic acid. This may increase the risk of dehydration, kidney problems, and low blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. Use caution when getting up from a sitting or lying position, and let your doctor know if you develop these symptoms. Keep yourself hydrated by drinking plenty of fluids unless otherwise directed. You should seek medical advice immediately if you have reduced oral intake (for example, due to acute illness) or increased fluid loss (for example, due to vomiting, diarrhea, or excessive heat exposure), as it may be appropriate to interrupt one or both medications temporarily under these circumstances. In addition, ethacrynic acid may interfere with blood glucose control and reduce the effectiveness of empagliflozin and other diabetic medications. Monitor your blood sugar levels closely. You may need a dose adjustment of your diabetic medications during and after treatment with ethacrynic acid. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the diuretic and hypotensive effects of loop diuretics. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, dehydration, acute kidney injury, and renal function impairment can occur after initiating treatment with SGLT-2 inhibitors, and the risk is increased with concomitant use of diuretics. Conversely, loop diuretics can cause hyperglycemia and may reduce the therapeutic effects of SGLT-2 inhibitors.

MANAGEMENT: Caution is advised during concomitant use of SGLT-2 inhibitors and loop diuretics, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. Blood glucose should also be monitored more closely. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.

Empagliflozin

Generic Name: empagliflozin

Brand name: Jardiance

Synonyms: n.a.

What is Empagliflozin?

Ethacrynic Sodium Injection

Generic Name: ethacrynic acid

Brand name: Edecrin, Edecrin Sodium, Sodium Edecrin

Synonyms: Ethacrynic acid, Ethacrynic Acid

What is Ethacrynic Sodium Injection?